Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors
Background. Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evalua...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2021/6632249 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556866147713024 |
|---|---|
| author | Mario Orozco-Morales Alejandro Avilés-Salas Norma Hernández-Pedro Rodrigo Catalán Graciela Cruz-Rico Ana Laura Colín-González Elsa Dosal-Mancilla Pedro Barrios-Bernal Oscar Arrieta |
| author_facet | Mario Orozco-Morales Alejandro Avilés-Salas Norma Hernández-Pedro Rodrigo Catalán Graciela Cruz-Rico Ana Laura Colín-González Elsa Dosal-Mancilla Pedro Barrios-Bernal Oscar Arrieta |
| author_sort | Mario Orozco-Morales |
| collection | DOAJ |
| description | Background. Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies. However, the clinical relevance of CD47 expression in LNET has remained unclear. Methods. We performed a retrospective study in which we analyzed tumor biopsies from 51 patients with a confirmed diagnosis of LNET that received treatment at our hospital. Then, we analyzed if there was any correlation between CD47 expression with any clinical or pathological characteristic. We also analyzed the prognostic significance of CD47, assessed as progression-free survival and overall survival. Results. A total of 51 patients with LNET were enrolled in our study. The mean age at diagnosis was 57.6 (±11.6) years; 30 patients were women (59%). 27.5% of patients were positive for CD47 expression, and 72.5% of patients showed a CD47 expression of less than 1% and were considered as negatives. In patients with high-grade tumors (this time defined as Ki‐67>40%), the positive expression of CD47 was strongly associated with an increased PFS. Albeit, these differences did not reach statistical significance when analyzing OS. Conclusion. Contrary to what happens in a wide range of hematologic and solid tumors, a higher expression of CD47 in patients with LNET is associated with a better progression-free survival, especially in patients with a Ki‐67≥40%. This “paradox” remains to be confirmed and explained by larger studies. |
| format | Article |
| id | doaj-art-09eeddcda4f745a092afc8f3402e001c |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-09eeddcda4f745a092afc8f3402e001c2025-02-03T05:44:08ZengWileyJournal of Immunology Research2314-88612314-71562021-01-01202110.1155/2021/66322496632249Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine TumorsMario Orozco-Morales0Alejandro Avilés-Salas1Norma Hernández-Pedro2Rodrigo Catalán3Graciela Cruz-Rico4Ana Laura Colín-González5Elsa Dosal-Mancilla6Pedro Barrios-Bernal7Oscar Arrieta8Thoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoPathology Department, Instituto Nacional de Cancerología (INCan), Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoThoracic Oncology Unit and Personalized Medicine Laboratoy, Instituto Nacional de Cancereología, Mexico City, MexicoBackground. Lung neuroendocrine tumors account for approximately 15% of all lung cancer cases. LNET are subdivided into typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), and small-cell lung cancer (SCLC). The Ki-67 index has been used for decades to evaluate mitotic counts however, the role of Ki-67 as a biomarker for assessing prognosis and guiding therapy in metastatic LNET still lacks feasible clinical validation. Recent clinical trials have indicated that inhibition of CD47 with anti-CD47 antibodies exerts a promising antitumor effect against several human malignancies, including NSCLC, melanoma, and hematologic malignancies. However, the clinical relevance of CD47 expression in LNET has remained unclear. Methods. We performed a retrospective study in which we analyzed tumor biopsies from 51 patients with a confirmed diagnosis of LNET that received treatment at our hospital. Then, we analyzed if there was any correlation between CD47 expression with any clinical or pathological characteristic. We also analyzed the prognostic significance of CD47, assessed as progression-free survival and overall survival. Results. A total of 51 patients with LNET were enrolled in our study. The mean age at diagnosis was 57.6 (±11.6) years; 30 patients were women (59%). 27.5% of patients were positive for CD47 expression, and 72.5% of patients showed a CD47 expression of less than 1% and were considered as negatives. In patients with high-grade tumors (this time defined as Ki‐67>40%), the positive expression of CD47 was strongly associated with an increased PFS. Albeit, these differences did not reach statistical significance when analyzing OS. Conclusion. Contrary to what happens in a wide range of hematologic and solid tumors, a higher expression of CD47 in patients with LNET is associated with a better progression-free survival, especially in patients with a Ki‐67≥40%. This “paradox” remains to be confirmed and explained by larger studies.http://dx.doi.org/10.1155/2021/6632249 |
| spellingShingle | Mario Orozco-Morales Alejandro Avilés-Salas Norma Hernández-Pedro Rodrigo Catalán Graciela Cruz-Rico Ana Laura Colín-González Elsa Dosal-Mancilla Pedro Barrios-Bernal Oscar Arrieta Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors Journal of Immunology Research |
| title | Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors |
| title_full | Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors |
| title_fullStr | Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors |
| title_full_unstemmed | Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors |
| title_short | Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors |
| title_sort | clinicopathological and prognostic significance of cd47 expression in lung neuroendocrine tumors |
| url | http://dx.doi.org/10.1155/2021/6632249 |
| work_keys_str_mv | AT marioorozcomorales clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT alejandroavilessalas clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT normahernandezpedro clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT rodrigocatalan clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT gracielacruzrico clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT analauracolingonzalez clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT elsadosalmancilla clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT pedrobarriosbernal clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors AT oscararrieta clinicopathologicalandprognosticsignificanceofcd47expressioninlungneuroendocrinetumors |